Vera Therapeutics, Inc.
NASDAQ:VERA · NASDAQ Global Market
+$0.09 today
Vol 1.50M · Avg 1.18M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.6%
avg -34.4%
ROIC
-46.3%
avg -89.8%
ROA
-40.8%
avg -77.7%
Analysis
ROA is currently the strongest return metric at -40.8% versus its period average of -77.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Marshall Fordyce | Founder, President, Chief Executive Officer & Director | $1.21M | — | 51 | $216,744.00 | 0.30% |
David L. Johnson | Chief Opearating Officer | $798,600.00 | — | 56 | $45,727.00 | 0.06% |
Robert Brenner | Chief Medical Officer | $797,040.00 | — | 58 | $50,947.00 | 0.07% |
Sean Grant | Chief Financial Officer | $793,920.00 | — | 41 | $114,181.00 | 0.16% |
William D. Turner | Chief Regulatory Officer | $737,880.00 | — | 59 | $45,313.00 | 0.06% |
Debra Charlesworth | Vice President of Corporate Communications | — | — | — | — | — |
Emma Haywood | Vice President of Marketing | — | — | — | — | — |
S. Sandra Park | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations | — | — | — | — | — |
Jane Wright-Mitchell | Chief Legal Officer & Secretary | — | — | 57 | $42,403.00 | 0.06% |
Joseph R. Young | Senior Vice President of Finance & Chief Accounting Officer | — | — | 54 | $38,589.00 | 0.05% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$5.53M
Sells
17
$4.99M
Net Sentiment
+$533,265.22
Net buying
Most Active
Fordyce Marshall
6 transactions
1–10 of 22
Analysis
Insiders reported 5 buys worth $5.53M and 17 sells worth $4.99M over the last 12 months. That adds up to net buying of $533,265.22. Fordyce Marshall was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
uniQure N.V.
NASDAQ:QURE
$2.99B
Pharvaris N.V.
NASDAQ:PHVS
$2.30B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.19B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.92B
Nuvation Bio Inc.
NYSE:NUVB
$1.89B
Immunome, Inc.
NASDAQ:IMNM
$1.75B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.66B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.50B
Biohaven Ltd.
NYSE:BHVN
$1.44B
Janux Therapeutics, Inc.
NASDAQ:JANX
$852.41M
Who manages VERA?
Vera Therapeutics, Inc. (VERA) lists 10 active executives. The top listed executive is Sean Grant, Chief Financial Officer.
Are VERA insiders buying or selling?
Recent insider activity shows net buying of $35.22M.
Explore More
Continue the stock analysis
Jump to another research area for this company.